Syneos Health (formerly InVentiv Health Incorporated and INC Research) is a NASDAQ listed American multinational contract research organization based in Morrisville, North Carolina. The company specializes in helping companies with late-stage clinical trials. In January 2018 INC Research acquired inVentiv Health, the parent company of a subsidiary, Syneos, and the resulting company was named Syneos Health.
INTRODUCTION:Factors associated with decline of hepatic function and increase in portal-systemic shunting, which herald clinical outcome in persons with compensated cirrhosis, are poorly characterized. We used cholate challenge to evaluate the associations of liver disease etiology, concomitant diabetes, and maintenance drug therapy, with the degree of hepatic dysfunction and portal-systemic shunting. METHODS:In the SHUNT-V study, there were 255 subjects with compensated (Child-Pugh class A) cirrhosis who underwent cholate challenge, involving oral administration of [2,2,4,4- 2 H] cholate and measurement of its serum concentrations at 20 and 60 minutes. Test outputs included a disease severity index (DSI) to assess global liver function and SHUNT% to assess portal systemic shunting. RESULTS:Eighty-seven percent of subjects were overweight, 65% were obese, 48% had metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), 51% had type 2 diabetes mellitus, 49% were taking anti-diabetic drugs, and 45% were taking lipid-lowering drugs. Laboratory values and clinical scores of MASLD/MASH subjects were similar to subjects with other etiologies for liver disease. In univariable regression, MASLD/MASH, diabetes mellitus, metformin, and statins were associated with lower DSI and SHUNT%. In multivariable regression, lower DSI was attributable to statins ( P = 0.0354) and metformin ( P = 0.0561). The combined use of lipid-lowering and anti-diabetic drugs, compared with no use, was associated with 19% reduction in DSI. CONCLUSION:Concomitant use of statins alone or in combination with metformin was independently associated with preserved hepatic function (DSI) and reduced portal-systemic shunting (SHUNT%).
BackgroundPeople with migraine report reduced health-related quality of life during ictal and interictal phases. However, most patient-reported outcome measures (PROMs) focus on impact during migraine episodes (ictal) or globally (both ictal and interictal), potentially neglecting interictal burden. This exploratory analysis evaluated correlations between the 4-item Migraine Interictal Burden Scale (MIBS-4) total score and other PROMs in people with migraine.MethodsA post hoc analysis was conducted using participant data from a galcanezumab phase 3, placebo-controlled, 3-month study, followed by a 3-month open-label extension in participants with prior treatment failures. Correlations were assessed between baseline MIBS-4 and disease characteristics, baseline MIBS-4 and demographics, and MIBS-4 and other PROMs/monthly migraine headache days at baseline and at Month (M) 6, using Spearman’s rank correlation coefficient (rs).ResultsA total of 462 participants were included (mean age: 45.8 years); 85.9% were female, 58.2% had episodic migraine and 41.8% had chronic migraine. At baseline, highest correlations with MIBS-4 were observed for Migraine Specific Quality of Life Questionnaire (MSQ)-total score, MSQ-Emotional Function (MSQ-EF), and the Patient Health Questionnaire (PHQ-9) score, which measures depressive symptoms (all p < 0.001). Correlation analysis between MIBS-4 and MSQ-total score revealed moderate correlation at baseline (rs:–0.53) that transitioned to moderate-high at M6 (rs:–0.70). MIBS-4 was moderately correlated with PHQ-9 score at baseline (rs:0.55) and M6 (rs:0.55). The Migraine Disability Assessment score transitioned from moderate-low correlation at baseline (rs:0.41) to moderate at M6 (rs: 0.53) and Generalized Anxiety Disorder score had moderate-low correlation at both time points (rs:0.42–0.47). MIBS-4 had moderate-negligible correlation with monthly migraine headache days at baseline (rs:0.21) and low correlation at Month 6 (rs:0.32).ConclusionInterictal burden, as assessed by MIBS-4, was moderately correlated with PROMs like MSQ, PHQ-9, and MIDAS, but moderate-negligible to low correlation was observed with monthly migraine headache days. These results indicate that interictal burden is a unique construct that is correlated with, but not fully captured by, other measures and should be considered when managing people with migraine.Clinical trial registrationClinicalTrials.gov identifier NCT03559257.
Continuous proportions measured on the same experimental unit often pose two challenges: influential interior extremes that inflate variance beyond the beta ceiling and residual dependence that invalidates independent-margin models. We introduce a Bayesian copula modeling approach that combines rectangular-beta margins, which temper influential interior extremes by reallocating mass from the peak to a uniform component, with a single-parameter copula to capture concordance. Gaussian, Gumbel, and Clayton copula families are fitted, and log marginal likelihoods are obtained via bridge sampling to guide model selection. Applied to two surveys 13 years apart (2003 and 2016) of Azorella selago cushion plants on sub-Antarctic Marion Island, the copula models outperform independence baselines in explaining percent dead stem cover. Accounting for between-year dependence reveals a positive west-slope effect and weakens the cushion size effect. Simulation results show negligible bias and near-nominal 95
Background: Lenalidomide is an immunomodulatory agent thought to inhibit the growth of del(5q) haematopoietic progenitors in myelodysplastic syndromes (MDS) that was approved for use in Europe for certain forms of these conditions in 2013.Objectives: This study aimed to identify the distribution of lenalidomide treatment and safety outcomes in patients with MDS in Europe among those treated within (on-label) and outside (off-label) of the European Commission-approved indication.Design: This observational, retrospective study of prospectively collected disease registry data (13 June 2013 to 1 May 2023) summarised lenalidomide treatment patterns and safety outcomes by on- and off-label treatment in 11 European countries.Methods: Safety outcomes included progression to acute myeloid leukaemia (AML), second primary malignancies (SPMs), adverse events (AEs) and all-cause mortality. Hazard ratios (HRs) and 95% CI were reported for progression to AML comparing on- to off-label treatment.Results: Among 523 qualifying patients, more were prescribed lenalidomide off-label (n = 345) than on-label (n = 157); label status was unknown in 21 patients prescribed lenalidomide. Progression to AML occurred in 10.2% of on-label patients and 13.0% of off-label patients (HR: 0.9; 95% CI: 0.4, 1.7). Solid tumours were the most common SPM (7.0% on-label, 1.7% off-label). Neutropenia (38.9% on-label, 33.3% off-label) and thrombocytopenia (36.9% on-label, 28.1% off-label) were the most common AEs. Death occurred in 53 on-label and 75 off-label patients. The most common causes of death were unknown (19.1% on-label, 4.3% off-label) or due to AML (3.2% on-label, 6.1% off-label).Conclusion: Analysis of real-world registry data indicated that off-label lenalidomide use in patients treated for MDS was common. Across the registries studied, the overall incidence of safety events of lenalidomide in patients with MDS was consistent in both on-label and off-label use, highlighting the importance of researching off-label use of lenalidomide in MDS.Trial registration: This study was registered with the EU Post-Authorisation Studies (PAS) Register: EUPAS22604.